okay I was wrong re the short sellers. The longer view is for a much higher valuation

The short sellers will pay the price. Stock is headed way up

The short sellers will pay the price. Stock is headed way up

Due diligence can be a bit*h

you were right

A real micro beast. The product pipeline is amazing!

Thanks. There have been several "close but no cigar" events.

What makes you think the takeover is finally coming?

Yesterday's presentation was informative, value and shows the great potential for ECOR

Agreed

Wassup sitting pretty?

Expected lifespan of company is 15 months

The technology is great. Unfortunately they have not been successful In commercializing.

Agreed. I find your comments insightful. Thanks for sharing.

Agreed. I find your comments insightful. Thanks for sharing.

Yes. The question is when

They have switched to a distributor. Pfizer is entering the market via the Biohaven acquisition. Little chance of improving in the commercial migraine market.

Even a blind squirrel finds nuts sometimes. Then again, moving ECOR forward takes more than luck. While a path to success may be present, the current team doesn’t see it. They may never see it.
So I reluctantly concede that your assessment is better.

I can see a path forward. Then again I have decades of experience. At some point they will either get a visionary or fail. A good strategy will support a higher valuation.

Good things come to those of us who waited

$0.40. Agreed

NXL has an impressive clinical pipeline!

Pfizer has taken a large position in the migraine market. Even ElectroCore has a better product they were unable to reach commercial users. Now they can only have a small share of voice.

Who is taking over?

Polyphemus, I agree with most everything that you post. I thank you for sharing your expert opinion. Not disagreeing with your strategy, but am still concerned about the time horizon. It might take longer to implement your strategy due to clinicians habit of utilizing pharmaceutical solutions. We recognize that stimulating the nerve produces the desired patient I response with close to zero side effects. It is still very difficult to convince clinicians to utilize a new, albeit better, treatment modality.

Agreed. Clearly it was a mistake to go after the migraine indication first. The question is can ECOR stay alive long enough to develop the other more lucrative indications. They have a good structure awaiting product.

Still here. At a loss for words after losing $$$.

Not sure what happened. Never previously observed this type of situation.

The reason the action was failure to file financial reports. They were given a couple of weeks to determine a mechanism to rectify. Haven’t heard how that is evolving.

What is your takeaway?

Agreed. They understand the science but not the market.

Anybody home?

What were sales in Q1?

Thank you. Very important information. There is a school of thought that suggests people with high levels of antibodies should not be vaccinated. This could potentially be a factor in the formation of blood clots.

We are in too much of a rush to vaccinate everybody, whether they need it or not

Personally I studied the issue before being vaccinated.

Thank you. Very important information. There is a school of thought that suggests people with high levels of antibodies should not be vaccinated. This could potentially be a factor in the formation of blood clots.

We are in too much of a rush to vaccinate everybody, whether they need it or not

Personally I studied the issue before being vaccinated.

The initial value will be the same as before the reverse split. Hopefully there is more upside potential.

Yes. While I don’t advise not looking, I expect mrk to reach an all time later this year. Dividend is not bad

Just quietly watching Jack.

We do need to identify the new CEO and his background.

Don’t know about the actual value of the federal contract. It would be easier to assess if we could see financial statements

How can we tell? Would like to see financial statements.

The last sec filing that I saw announced a contract with the federal government. Will future RFPs include the specification of the drive?

The question on the table is the wording of federal contracts. Will this minor change be included in the specs?